APA

Brown L. A., Johnson K., Leung S., Bismar T. A., Benítez J., Foulkes W. D. & Huntsman D. G. (20100820). Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. : Breast cancer research and treatment.

Chicago

Brown Lindsay A, Johnson Karynn, Leung Samuel, Bismar Tarek A, Benítez Javier, Foulkes William D and Huntsman David G. 20100820. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. : Breast cancer research and treatment.

Harvard

Brown L. A., Johnson K., Leung S., Bismar T. A., Benítez J., Foulkes W. D. and Huntsman D. G. (20100820). Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. : Breast cancer research and treatment.

MLA

Brown Lindsay A, Johnson Karynn, Leung Samuel, Bismar Tarek A, Benítez Javier, Foulkes William D and Huntsman David G. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. : Breast cancer research and treatment. 20100820.